Status:
WITHDRAWN
A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD
Lead Sponsor:
Syntara
Conditions:
COPD
Exacerbation
Eligibility:
All Genders
35-75 years
Phase:
PHASE1
PHASE2
Brief Summary
COPD is a major cause of ill health and death in Australia with 40,000 hospital admissions, and a national cost of $898,000,000 annually. The gold standard treatment of COPD is steroids for inflammati...
Eligibility Criteria
Inclusion
- FEV1 \> 35% predicted
- COPD
- Exacerbation
- Inpatient
Exclusion
- Pneumonia
- CO2 retention
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00446667
Start Date
October 1 2006
End Date
June 1 2008
Last Update
September 28 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia, 2087
2
St George Hospital
Sydney, New South Wales, Australia